Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker

Abstract

Improved biomarkers are needed for early cancer detection, risk stratification, treatment selection, and monitoring treatment response. Although proteins can be useful blood-based biomarkers, many have limited sensitivity or specificity for these applications. Long INterspersed Element-1 (LINE-1) open reading frame 1 protein (ORF1p) is a transposable element protein overexpressed in carcinomas and high-risk precursors during carcinogenesis with negligible expression in normal tissues, suggesting ORF1p could be a highly specific cancer biomarker. To explore ORF1p as a blood-based biomarker, we engineered ultrasensitive digital immunoassays that detect mid-attomolar (10−17 mol/L) ORF1p concentrations in plasma across multiple cancers with high specificity. Plasma ORF1p shows promise for early detection of ovarian cancer, improves diagnostic performance in a multianalyte panel, provides early therapeutic response monitoring in gastroesophageal cancers, and is prognostic for overall survival in gastroesophageal and colorectal cancers. Together, these observations nominate ORF1p as a multicancer biomarker with potential utility for disease detection and monitoring.

Significance:

The LINE-1 ORF1p transposon protein is pervasively expressed in many cancers and is a highly specific biomarker of multiple common, lethal carcinomas and their high-risk precursors in tissue and blood. Ultrasensitive ORF1p assays from as little as 25 μL plasma are novel, rapid, cost-effective tools in cancer detection and monitoring.

See related commentary by Doucet and Cristofari, p. 2502.

This article is featured in Selected Articles from This Issue, p. 2489

Funding

NCI NIH HHS

R01 CA240924

NCI NIH HHS

P50 CA240243

NIBIB NIH HHS

F32 EB029777

NCI NIH HHS

R01 CA276112

NCI NIH HHS

P50 CA228991

NCI NIH HHS

T32 CA009216

NCI NIH HHS

U2C CA271871

NCI NIH HHS

R01 CA240816

NCI NIH HHS

U01 CA228963

NCI NIH HHS

P50 CA127003

NCI NIH HHS

P30 CA006516

NIGMS NIH HHS

P41 GM109824

NIGMS NIH HHS

R01 GM130680

NIDDK NIH HHS

K08 DK129824

NCI NIH HHS

U01 CA152990

NIGMS NIH HHS

R01 GM126170

NCI NIH HHS

U01 CA233364

National Institutes of Health

R01GM130680

National Institutes of Health

K08DK129824

National Institutes of Health

F32EB029777

National Institutes of Health

R01CA240924

National Institutes of Health

U01CA228963

National Institutes of Health

P41GM109824

National Institutes of Health

T32CA009216

National Institutes of Health

U01CA233364

National Institutes of Health

U2CCA271871

National Institutes of Health

U01CA152990

National Institutes of Health

R01GM126170

National Institutes of Health

P50CA228991 Ovarian SPORE

National Institutes of Health

P30CA006516 Incubator

Break Through Cancer

Friends For an Earlier Breast Cancer Test

Minnesota Ovarian Cancer Alliance

U.S. Department of Defense

W81XWH-22-1-0852

Canary Foundation

Gray Foundation

The Concord (MA) Detect Ovarian Cancer Early Fund

Good Ventures Foundation

Friends of Dana-Farber Cancer Institute

Dana-Farber Cancer Institute

Dana-Farber/Harvard Cancer Center

ACD-Biotechne

Robert L. Fine Cancer Research Foundation

Worldwide Cancer Research

19-0223

Robertson Therapeutic Development Fund

Nile Albright Research Foundation

Vincent Memorial Research Foundation

Stand Up To Cancer

Gastric Cancer Interception Research Team Grant (SU2C-AACR-DT-30-20)

National Institutes of Health

P50CA240243 ovarian SPORE